Business Wire

T.A.C-THE-AYURVEDA-CO.

17.3.2023 10:28:38 CET | Business Wire | Press release

Share
T.A.C raises USD 12.2 Mn in Series A round led by Sixth Sense Ventures

T.A.C - The Ayurveda Co., India's first and fastest-growing D2C omnichannel Ayurvedic lifestyle brand, has raised USD 12.2 Mn in its Series A funding round from India's largest consumer VC fund, Sixth Sense Ventures. It also saw participation from actress Kajal Agarwal, notable start-up founders and venture debt funds. It was also seen on ‘Shark Tank India’ special episode number 51.

The brand has shown unprecedented growth over the past 10 months, growing over 300%, with a strong omni-channel distributor across retail touchpoints and online channels. T.A.C has recently forayed into global markets, starting with MEA region with its Dubai launch.

Within a short span from inception T.A.C has acquired more than 2 million consumers with its bestselling Kumkumadi, Eladi & Methi ranges, and managed to raise funds even during the global funding winter. The funds will also be used for ‘digitalization of Ayurveda’ with soon to launch ‘T.A.C App’ - a revolutionary mobile-based application where users can get consultation about ayurvedic healthcare across the globe.

Shreedha Singh, Co-founder & CEO T.A.C. and Khadi Essentials added, “We will use this to replicate the love we have amassed from our millions of consumers in India to other regions. Our Kumkumadi face care range for radiance & youthful skin is most loved and our formulations are Ayurvedic with global certifications & and clinically proven results.”

Param Bhargava, Founder, T.A.C. and Khadi Essentials said, “I am excited to see the tremendous growth potential in the Ayurvedic Beauty and Personal Care (BPC) category worldwide, which is expected to grow from $12bn to $30bn in the next five years. We will be happy to partner with right stakeholders who can disrupt & exponentially grow Ayurveda & T.A.C across regions.”

Nikhil Vora, Founder & CEO Sixth Sense Ventures said, “T.A.C is garnering shelf space in areas dominated by incumbents to become an omnichannel global Beauty & Wellness brand. Thrilled to partner with the super passionate and determined duo, Param and Shreedha, to realise their vision!”

T.A.C's vision is to HEAL, which stands for Help Embrace an Ayurvedic Life. Recognizing the life-changing potential of Ayurveda, the brand offers uncompromised, pure and top-notch quality.

Choose Ayurveda, Choose T.A.C

Website - https://theayurvedaco.com/

Instagram - https://www.instagram.com/theayurvedaco/

LinkedIn - https://www.linkedin.com/company/the-ayurveda-company

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230316005347/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

Multi-Color Corporation Receives Court Approval of First Day Motions4.2.2026 21:30:00 CET | Press release

Obtains Interim Approval to Access $125 Million of DIP FinancingGlobal Operations and Services to Customers Continue in Normal Course Without Interruption During Restructuring Process; All Trade Vendors and Suppliers to be Paid in Full Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced that it has received approval from the U.S. Bankruptcy Court for the District of New Jersey (the “Court”) for first day relief related to its prepackaged Chapter 11 filed on January 29, 2026. The approved relief affirms that the Company will operate in the normal course, pay all trade vendors and suppliers in full, and maintain a strong liquidity position during the restructuring. As part of this relief, the Court granted MCC immediate access to $125 million of $250 million in debtor-in-possession (“DIP”) new money financing, provided by certain holders of MCC’s secured first lien debt and its equity sponsor, CD&R. This funding will capitalize the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye